Osimertinib in EGFR Mutation–Positive Advanced NSCLC

N Engl J Med. 2018 Mar 29;378(13):1261. doi: 10.1056/NEJMc1801669.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms
  • Mutation
  • Piperazines*

Substances

  • Acrylamides
  • Aniline Compounds
  • Piperazines
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors